The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
List view / Grid view
British Generic Manufacturers Association (BGMA)
Filter the results
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic and biosimilar medicines and promotes the development and understanding of the generic and biosimilar medicines industry in the United Kingdom.
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
25 February 2015 | By British Generic Manufacturers Association
The onset of biosimilar competition in the UK in Infliximab is another significant milestone in the development of the sector in this country according to the British Generic Manufacturers Association (BGMA).
13 November 2014 | By British Generic Manufacturers Association
Price cuts for branded generic medicines as part of proposed Government changes to the statutory scheme to control the prices of branded health service medicines will undermine innovation, create uncertainty, reduce competition and ultimately undermine patient benefits...
Response from the British Generic Manufacturers Association (BGMA) to a new report issued today by the Academy of Medical Royal Colleges...
BGMA welcomes EU General Court ruling that AstraZeneca abused its dominant position by preventing the marketing of generic omeprazole.